Table 1.
Clinical and imaging characteristics of the included patients.
| Characteristics | Training dataset | Validation dataset | Test dataset | F/χ2 | P |
|---|---|---|---|---|---|
| n = 659 | n = 80 | n = 200 | |||
| Age, mean ± SD(y) | 68.1 ± 7.8 | 67.5 ± 5.4 | 67.7 ± 7.4 | 0.53 | 0.58 |
| Prostate cancer, n (%) | 425 (64.5) | 41 (51.3) | 100 (50) | 17.22 | <0.01 |
| Non prostate cancer, n (%) | 234 (35.5) | 39 (48.7) | 100 (50) | ||
| tPSA level (ng/ml) | 17.8 ± 22.2 | 14.9 ± 15.7 | 15.9 ± 22.1 | 0.91 | 0.40 |
| Prostate cancer | 15.3 ± 21.3 | 22.0 ± 23.1 | 13.1 ± 17.7 | 0.04 | 0.96 |
| Non prostate cancer | 9.0 ± 5.3 | 7.35 ± 4.7 | 9.1 ± 6.4 | 1.18 | 0.31 |
| Prostate cancer lesion numbers | 500 | 59 | 127 | ||
| Prostate cancer zone distribution, n (%) | |||||
| PZ | 315 (63.0) | 42 (71.2) | 78 (61.4) | 5.37 | 0.49 |
| TZ | 146 (29.2) | 10 (16.9) | 38(29.9) | ||
| AFS | 3 (0.6) | 0 | 1 (0.8) | ||
| Mixed | 36 (7.2) | 7 (11.9) | 10 (7.9) |
The data are reported as the mean ± standard deviations.
PSA, prostate-specific antigen; PZ, peripheral zone; TZ, transitional zone; AFS, anterior fibromuscular stroma.